Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.40 | N/A | -1.96% |
management commentary, guidance changes, and full analysis available with Pro.
| -1.96% |
Tone: Defensive
Overall, management expressed caution regarding current market conditions. They are prioritizing cost control while navigating challenges.
Management highlighted ongoing challenges in the market.
They emphasized a focus on cost management and operational efficiency.
Amgen's earnings report showed a slight miss on EPS, which contributed to a modest decline in the stock price. Investors may be concerned about the lack of guidance and the challenges mentioned by management. The stock's reaction reflects a cautious sentiment in the market as the company navigates these issues.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
IBM CORP
Jan 22, 2013